Skip to main content
Log in

Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

A difference in clinical manifestations of paroxysmal nocturnal hemoglobinuria (PNH) among different races has been suggested. The aim of this study was to clarify whether the clinical characteristics of patients with PNH in the International PNH Registry differ by ethnic background. Patients, who were eculizumab naïve at baseline and had ≥ 1% PNH clone size, were eligible for this analysis. Totally, 1793 patients were enrolled and divided into two cohorts, Asian (N = 246) and non-Asian (N = 1547). The Asian cohort was further divided into Asians in Asia cohort (N = 202) and Asians in non-Asia cohort (N = 44), based on geographical region. The Asian cohort had significantly higher PNH clone size in granulocytes, higher lactate dehydrogenase levels, and lower hemoglobin levels. However, the frequencies of symptoms including abdominal pain, backache, easy bleeding, fatigue and headache at baseline were significantly lower in the Asian cohort. The proportion of patients with a history of thromboembolism (TE) was significantly lower in the Asian than in the non-Asian cohort (3.6% vs. 8.9%, P < 0.01); however, there was no difference between Asians in Asia and Asians in non-Asia (3.3% vs. 4.9%, P = 0.61). These findings suggested that genetic factors may play a stronger role in developing TE than lifestyle factors in PNH patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–8.

    Article  CAS  PubMed  Google Scholar 

  2. Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318–20.

    Article  CAS  PubMed  Google Scholar 

  3. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–11.

    Article  CAS  PubMed  Google Scholar 

  5. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine. 2004;83:193–207.

    Article  PubMed  Google Scholar 

  6. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–7.

    Article  CAS  PubMed  Google Scholar 

  7. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–9.

    Article  CAS  PubMed  Google Scholar 

  8. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–43.

    Article  CAS  PubMed  Google Scholar 

  9. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7.

    Article  CAS  PubMed  Google Scholar 

  10. Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2018;107:656–65.

    Article  CAS  PubMed  Google Scholar 

  11. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–92.

    Article  CAS  PubMed  Google Scholar 

  12. Schrezenmeier H, Muus P, Socie G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99:922–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Socie G, Schrezenmeier H, Muus P, Lisukov I, Röth A, Kulasekararaj A, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry. Intern Med J. 2016;46:1044–53.

    Article  CAS  PubMed  Google Scholar 

  14. Chou WC, Huang WH, Wang MC, Chang CS, Yeh SP, Chiou TJ, et al. Characteristics of Taiwanese patients of PNH in the international PNH registry. Thromb J. 2016;14(Suppl 1):39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112:3099–106.

    Article  CAS  PubMed  Google Scholar 

  16. Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, et al. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH Registry. J Korean Med Sci. 2016;31:214–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Munoz-Linares C, Ojeda E, Fores R, Pastrana M, Cabero M, Morillo D, et al. Paroxysmal nocturnal hemoglobinuria: a single Spanish center’s experience over the last 40 yr. Eur J Haematol. 2014;93:309–19.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97:749–57.

    Article  PubMed  Google Scholar 

  19. Wang HC, Kuo CY, Liu IT, Chen TY, Chang YH, Lin SJ, et al. Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: a multicenter investigation. Kaohsiung J Med Sci. 2017;33:405–10.

    Article  PubMed  Google Scholar 

  20. Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016;103:649–54.

    Article  PubMed  Google Scholar 

  21. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985–96.

    Article  CAS  PubMed  Google Scholar 

  22. Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood. 1982;60:20–3.

    Article  CAS  Google Scholar 

  23. Issaragrisil S, Piankijagum A, Tang-naitrisorana Y. Corticosteroids therapy in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 1987;25:77–83.

    Article  CAS  PubMed  Google Scholar 

  24. Shichishima T, Saitoh Y, Noji H, Terasawa T, Maruyama Y. In vivo effects of various therapies on complement-sensitive erythrocytes in paroxysmal nocturnal hemoglobinuria. Int J Hematol. 1996;63:291–302.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to all doctors and paramedics who reported data to the International PNH Registry. The study was funded and analyzed by Alexion Pharmaceutical, Inc.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Jong Wook Lee or Shinichiro Okamoto.

Ethics declarations

Conflict of interest

MS, JN, YK, JWL and SO receive honoraria from Alexion, JN, YK and JWL receive research funding from Alexion Pharma G.K., AW receives employment, and equity ownership from Alexion Pharmaceuticals, Inc.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakurai, M., Jang, J.H., Chou, WC. et al. Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol 110, 411–418 (2019). https://doi.org/10.1007/s12185-019-02699-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02699-7

Keywords

Navigation